Acquisitions (Tables)

3 Months Ended

Mar. 31, 2016

Business Acquisition [Line Items]

Schedule of Acquisition Related Costs

Acquisition-related costs associated with our business combinations for the years ended for the three months ended, March 31, 2016 and 2015 include the following:

	Three months ended March 31,
	2016		2015
Transaction costs (1)	$	375	$	—
Integration costs	964		—
	$	1,339	$	—
(1) Transaction costs include investment advisory, legal, and accounting fees

Synageva BioPharma Corp.

Business Acquisition [Line Items]

Schedule of Business Acquisitions, by Acquisition

The aggregate consideration to acquire Synageva consisted of:

Stock consideration	$	4,917,810
Cash consideration	4,565,524
Total purchase price	$	9,483,334

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The following table summarizes the estimated fair values of assets acquired and liabilities assumed:

Cash	$	626,217
Inventory	23,880
In-process research and development (IPR&D)	4,236,000
Deferred tax liabilities, net	(171,638		)
Other assets and liabilities	(26,373		)
Net assets acquired	4,688,086
Goodwill	4,795,248
Total purchase price	$	9,483,334